Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
This analysis assessed the effect of lenalidomide on progression-free survival (PFS). Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenali...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194066/ |